⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRDF News
Cardiff Oncology, Inc. Common Stock
Form 8-K
sec.gov
CRDF
Form 8-K
sec.gov
CRDF
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
globenewswire.com
CRDF
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
globenewswire.com
CRDF
Form 8-K
sec.gov
CRDF
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
globenewswire.com
CRDF
Form 8-K
sec.gov
CRDF
Form 8-K
sec.gov
CRDF
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
globenewswire.com
CRDF
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CRDF